Managing dialysis patients who develop anemia caused by chronic kidney disease: focus on peginesatide
Amanda Valliant, R Michael Hofmann Division of Nephrology, University of Wisconsin, Madison, WI, USA Abstract: Anemia in chronic kidney disease is a prevalent and expensive problem in the United States, and it is well documented that anemia worsens as glomerular filtration rates decline. The complic...
Guardado en:
Autores principales: | Valliant A, Hofmann RM |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/74f04593918841b5b15234e020eb857f |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Lessons learned from peginesatide in the treatment of anemia associated with chronic kidney disease in patients on dialysis
por: Kaushik T, et al.
Publicado: (2013) -
A Population Pharmacokinetic and Pharmacodynamic Analysis of Peginesatide in Patients with Chronic Kidney Disease on Dialysis.
por: Himanshu Naik, et al.
Publicado: (2013) -
A real-world longitudinal study of anemia management in non-dialysis-dependent chronic kidney disease patients: a multinational analysis of CKDopps
por: Marcelo Barreto Lopes, et al.
Publicado: (2021) -
Effects of blood urea nitrogen independent of the estimated glomerular filtration rate on the development of anemia in non-dialysis chronic kidney disease: The results of the KNOW-CKD study.
por: Hyo Jin Kim, et al.
Publicado: (2021) -
Perfluoroalkyl substances and kidney function in chronic kidney disease, anemia, and diabetes
por: Conway BN, et al.
Publicado: (2018)